Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an update.
Atomo Diagnostics Limited reported a 7% decrease in revenue from ordinary activities, amounting to AUD 3,792,359 for the period ending June 30, 2025. Despite this, the company managed to reduce its loss from ordinary activities after tax by 27%, bringing it down to AUD 4,970,934. The basic and diluted earnings per share improved from the previous year, although no dividends were declared. The net tangible asset per ordinary security also decreased from 1.25 AUD cents in 2024 to 0.72 AUD cents in 2025, reflecting a challenging financial period. The financial statements have been audited with an unmodified opinion, and the company plans to hold its Annual General Meeting on or about October 31, 2025.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited operates in the medical diagnostics industry, focusing on the development and commercialization of rapid diagnostic test devices. The company is known for its innovative point-of-care testing solutions, which aim to improve healthcare accessibility and outcomes.
Average Trading Volume: 1,613,369
Technical Sentiment Signal: Hold
Current Market Cap: A$14.58M
See more data about AT1 stock on TipRanks’ Stock Analysis page.